In addition, research has demonstrated that MXD3 loss has a significant impact on the stem cell features of PRAD cells.[27] As an additional point of interest, MXD3, which is classified as an onco-immunological biomarker, has been linked to the microenvironment of the tumor, as well as to prognoses, disease stage, and individual responses to various cancer treatments. This evidence concerns the gene MXD3 and neoplasm.